U.S. markets closed

BeiGene, Ltd. (BEIGF)

OTC Markets OTCPK - OTC Markets OTCPK Precio retrasado. Moneda en USD.
Añadir a la lista de seguimiento
12.580.00 (0.00%)
Al cierre: 12:35PM EDT

BeiGene, Ltd.

94 Solaris Avenue
Camana Bay KY1-1108
Cayman Islands
345-949-4123
https://www.beigene.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo10,000

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. John V. OylerCo-Founder, Executive Chairman & CEO2.43MN/D1968
Dr. Xiaobin Wu Ph.D.President & COO1.7MN/D1962
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder4.42MN/D1963
Ms. Julia WangCFO & Principal Financial Officer1.07MN/D1971
Mr. Chan LeeGeneral Counsel & Senior VP1.01MN/D1968
Mr. Wang Lai Ph.D.Global Head of R&D1.12MN/D1977
Mr. Titus B. BallVP & Chief Accounting OfficerN/DN/D1973
Ms. Liza HeapesHead of Investor RelationsN/DN/DN/D
Mr. Yang JiChief Compliance OfficerN/DN/DN/D
Dr. Yan QiSenior VP & Head of Public Affairs - Greater ChinaN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Gestión corporativa

La calificación ISS Governance QuickScore de BeiGene, Ltd. a partir del 1 de junio de 2024 es 7. Las puntuaciones principales son Auditoría: 7; Junta: 5; Derechos del accionista: 6; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.